Cabaletta Bio, Inc. (CABA)
1.585
+0.06
(+4.28%)
USD |
NASDAQ |
Oct 29, 16:00
1.585
0.00 (0.00%)
After-Hours: 20:00
Cabaletta Bio Enterprise Value : 66.46M for Oct. 29, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 29, 2026 | 66.46M |
| October 28, 2026 | 55.56M |
| October 27, 2026 | 44.65M |
| October 26, 2026 | 27.04M |
| October 23, 2026 | 47.17M |
| October 22, 2026 | 55.56M |
| October 21, 2026 | 58.91M |
| October 20, 2026 | 70.65M |
| October 19, 2026 | 48.85M |
| October 16, 2026 | 37.11M |
| October 15, 2026 | 60.59M |
| October 14, 2026 | 72.33M |
| October 13, 2026 | 84.07M |
| October 12, 2026 | 100.84M |
| October 09, 2026 | 124.32M |
| October 08, 2026 | 127.68M |
| October 07, 2026 | 131.03M |
| October 06, 2026 | 139.42M |
| October 05, 2026 | 149.48M |
| October 02, 2026 | 136.06M |
| October 01, 2026 | 117.62M |
| September 30, 2026 | 122.65M |
| September 29, 2026 | 132.71M |
| September 28, 2026 | 136.06M |
| September 25, 2026 | 147.81M |
| Date | Value |
|---|---|
| September 24, 2026 | 162.06M |
| September 23, 2026 | 172.96M |
| September 22, 2026 | 219.93M |
| September 21, 2026 | 213.22M |
| September 18, 2026 | 228.31M |
| September 17, 2026 | 233.35M |
| September 16, 2026 | 218.25M |
| September 15, 2026 | 235.86M |
| September 14, 2026 | 288.70M |
| September 11, 2026 | 258.51M |
| September 10, 2026 | 260.18M |
| September 09, 2026 | 288.70M |
| September 08, 2026 | 349.08M |
| September 04, 2026 | 382.62M |
| September 03, 2026 | 384.30M |
| September 02, 2026 | 399.40M |
| September 01, 2026 | 354.11M |
| August 31, 2026 | 322.24M |
| August 28, 2026 | 323.92M |
| August 27, 2026 | 367.53M |
| August 26, 2026 | 345.72M |
| August 25, 2026 | 340.69M |
| August 24, 2026 | 320.56M |
| August 21, 2026 | 325.60M |
| August 20, 2026 | 335.66M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 566.80M |
| Amgen, Inc. | 292.39B |
| Anika Therapeutics, Inc. | 278.45M |
| BioCryst Pharmaceuticals, Inc. | 2.658B |
| Imunon, Inc. | 4.867M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -51.02M |
| Total Expenses (Quarterly) | 51.02M |
| EPS Diluted (Quarterly) | -0.3375 |
| Earnings Yield | -99.80% |
| Normalized Earnings Yield | -99.80 |